Bacterium, FDA Approval and Immune Response - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bacterium

FDA Approval

Immune Response

Merck’s Next-Generation Pneumonia Vaccine Gets FDA Approval

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20.

FDA Approval

FDA Approval Vaccination Vaccine Immune Response

Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine

Pharmaceutical Technology

OCTOBER 28, 2022

What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20. In June 2021, the FDA approved Pfizer’s Prevnar 20 for adult use, although a nod for paediatric use is pending. According to the UK’s National Health Service (NHS), there are over 90 strains of this bacterium.

Vaccination

Vaccination Vaccine Marketing Bacteria

Merck’s Next-Generation Pneumonia Vaccine Gets FDA Approval

Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine

Stay Connected